600420 国药现代
交易中 02-26 13:30:21
资讯
新帖
简况
国药现代(600420.SH)：盐酸米那普仑获得化学原料药上市申请批准
智通财经 · 02-24 17:02
国药现代(600420.SH)：盐酸米那普仑获得化学原料药上市申请批准
国药现代最新公告：公司及下属子公司51个药品拟中选国家集采药品接续采购
证券之星 · 02-11
国药现代最新公告：公司及下属子公司51个药品拟中选国家集采药品接续采购
每周股票复盘：国药现代（600420）2025年净利降12.85%
证券之星 · 02-01
每周股票复盘：国药现代（600420）2025年净利降12.85%
国药现代发布2025年度业绩快报，盈利9.444亿元
证券之星 · 01-26
国药现代发布2025年度业绩快报，盈利9.444亿元
国药现代：公司积极推进缓控释、膜剂等创新技术平台建设
证券日报 · 01-23
国药现代：公司积极推进缓控释、膜剂等创新技术平台建设
每周股票复盘：国药现代（600420）注射用哌拉西林钠通过一致性评价
证券之星 · 01-18
每周股票复盘：国药现代（600420）注射用哌拉西林钠通过一致性评价
国药现代（600420）披露全资子公司药品通过仿制药一致性评价，1月12日股价上涨0.76%
证券之星 · 01-12
国药现代（600420）披露全资子公司药品通过仿制药一致性评价，1月12日股价上涨0.76%
国药现代(600420.SH)子公司注射用哌拉西林钠通过仿制药一致性评价
智通财经 · 01-12
国药现代(600420.SH)子公司注射用哌拉西林钠通过仿制药一致性评价
国药现代（600420）披露全资子公司获得药品注册证书，12月25日股价下跌0.1%
证券之星 · 2025-12-25
国药现代（600420）披露全资子公司获得药品注册证书，12月25日股价下跌0.1%
国药现代(600420.SH)子公司获得富马酸喹硫平缓释片药品注册证书
智通财经 · 2025-12-25
国药现代(600420.SH)子公司获得富马酸喹硫平缓释片药品注册证书
国药现代（600420）披露选举第九届董事会成员，12月24日股价上涨0.2%
证券之星 · 2025-12-24
国药现代（600420）披露选举第九届董事会成员，12月24日股价上涨0.2%
国药现代（600420）披露拟变更经营范围并修订公司章程，12月15日股价上涨0.1%
证券之星 · 2025-12-15
国药现代（600420）披露拟变更经营范围并修订公司章程，12月15日股价上涨0.1%
国药现代（600420）披露全资子公司获得药品注册证书，12月11日股价上涨0.79%
证券之星 · 2025-12-11
国药现代（600420）披露全资子公司获得药品注册证书，12月11日股价上涨0.79%
国药现代(600420.SH)：布美他尼注射液获得药品注册证书
智通财经 · 2025-12-11
国药现代(600420.SH)：布美他尼注射液获得药品注册证书
国药现代（600420）披露全资孙公司获得化学原料药上市申请批准通知书，12月9日股价下跌0.78%
中金财经 · 2025-12-10
国药现代（600420）披露全资孙公司获得化学原料药上市申请批准通知书，12月9日股价下跌0.78%
国药现代(600420.SH)：原料药阿戈美拉汀上市申请获批准
智通财经 · 2025-12-09
国药现代(600420.SH)：原料药阿戈美拉汀上市申请获批准
国药现代（600420）披露独立董事候选人提名公告，12月8日股价下跌0.48%
证券之星 · 2025-12-08
国药现代（600420）披露独立董事候选人提名公告，12月8日股价下跌0.48%
国药现代(600420.SH)子公司获盐酸氢吗啡酮注射液药品注册证书
智通财经 · 2025-11-28
国药现代(600420.SH)子公司获盐酸氢吗啡酮注射液药品注册证书
每周股票复盘：国药现代（600420）选举王香芬为职工董事
证券之星 · 2025-11-23
每周股票复盘：国药现代（600420）选举王香芬为职工董事
国药现代（600420）披露选举职工董事公告，11月21日股价下跌2.21%
证券之星 · 2025-11-21
国药现代（600420）披露选举职工董事公告，11月21日股价下跌2.21%
加载更多
公司概况
公司名称：
上海现代制药股份有限公司
所属行业：
医药制造业
上市日期：
2004-06-16
主营业务：
上海现代制药股份有限公司的主营业务是医药产品研发、生产与销售。公司的主要产品是医药中间体、原料药、化学制剂、动物疫苗、大健康。至报告期末，公司累计通过一致性评价项目（含视同）151个，其中通过自主研发和BD项目引进获得新产品批准文号59个。
发行价格：
8.08
{"stockData":{"symbol":"600420","market":"SH","secType":"STK","nameCN":"国药现代","latestPrice":10.62,"timestamp":1772083821000,"preClose":10.7,"halted":0,"volume":5685400,"delay":0,"changeRate":-0.0075,"floatShares":1341000000,"shares":1341000000,"eps":0.6937,"marketStatus":"交易中","change":-0.08,"latestTime":"02-26 13:30:21","open":10.72,"high":10.74,"low":10.6,"amount":60594900,"amplitude":0.0131,"askPrice":10.63,"askSize":46,"bidPrice":10.62,"bidSize":1047,"shortable":0,"etf":0,"ttmEps":0.6937,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1772089200000},"marketStatusCode":2,"adr":0,"adjPreClose":10.7,"symbolType":"stock","openAndCloseTimeList":[[1772069400000,1772076600000],[1772082000000,1772089200000]],"highLimit":11.77,"lowLimit":9.63,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1341172692,"isCdr":false,"pbRate":1.05,"roa":"--","peRate":15.309211,"roe":"5.93%","epsLYR":0.808,"committee":0.524828,"marketValue":14243000000,"turnoverRate":0.0042,"status":1,"floatMarketCap":14243000000},"requestUrl":"/m/hq/s/600420","defaultTab":"news","newsList":[{"id":"2613796206","title":"国药现代(600420.SH)：盐酸米那普仑获得化学原料药上市申请批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2613796206","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613796206?lang=zh_cn&edition=full","pubTime":"2026-02-24 17:02","pubTimestamp":1771923765,"startTime":"0","endTime":"0","summary":"智通财经APP讯，国药现代 发布公告，近日，公司全资孙公司江苏威奇达药业有限公司收到国家药品监督管理局核准签发的关于原料药盐酸米那普仑的《化学原料药上市申请批准通知书》。盐酸米那普仑是由法国皮尔法伯公司研发推广的一种口服选择性5-羟色胺和去甲肾上腺素再吸收抑制剂，用于治疗重度抑郁症。上述事项不会对公司当期经营业绩产生重大影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406690.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0082","BK0132","BK0020","BK0010","BK0239","600420"],"gpt_icon":0},{"id":"2610936167","title":"国药现代最新公告：公司及下属子公司51个药品拟中选国家集采药品接续采购","url":"https://stock-news.laohu8.com/highlight/detail?id=2610936167","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610936167?lang=zh_cn&edition=full","pubTime":"2026-02-11 18:59","pubTimestamp":1770807598,"startTime":"0","endTime":"0","summary":"国药现代(600420.SH)公告称，公司及下属子公司参加了国家集采药品第1-8批协议期满品种接续采购，合计51个药品拟中选。主要拟中选药品包括硝苯地平控释片、注射用甲泼尼龙琥珀酸钠、苯磺酸氨氯地平片、头孢呋辛酯片等。2024年度和2025年前三季度，这些药品的销售收入分别占公司同期营业收入的20.59%和23.15%。公司表示，中选结果有利于稳固现有市场份额，提升品牌影响力，但对当期经营业绩不会产生重大影响。最终中选情况、合同签订和市场销售执行等存在不确定性。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021100031719.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0082","BK0010","BK0132","BK0239","BK0020","600420"],"gpt_icon":0},{"id":"2608070630","title":"每周股票复盘：国药现代（600420）2025年净利降12.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608070630","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608070630?lang=zh_cn&edition=full","pubTime":"2026-02-01 04:13","pubTimestamp":1769890389,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，国药现代报收于10.63元，较上周的10.59元上涨0.38%。业绩披露要点业绩快报国药现代近日即将发布2025年年报，根据1月26日发布的业绩快报，归属净利润盈利9.444亿元，同比减少12.85%。2025年度业绩快报上海现代制药股份有限公司发布2025年度业绩快报，营业总收入9,363,062,749.56元，同比下降14.40%；营业利润1,314,013,493.87元，同比下降25.00%；归属于上市公司股东的净利润944,379,815.55元，同比下降12.85%。本次计提减少公司2025年度合并报表利润总额13,395.59万元，上述数据未经审计。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020100001543.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","BK0010","600420","BK0020","BK0082","BK0239"],"gpt_icon":0},{"id":"2606192602","title":"国药现代发布2025年度业绩快报，盈利9.444亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2606192602","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606192602?lang=zh_cn&edition=full","pubTime":"2026-01-26 18:33","pubTimestamp":1769423590,"startTime":"0","endTime":"0","summary":"证券之星消息，国药现代近日即将发布2025年年报，根据1月26日发布的业绩快报，归属净利润盈利9.444亿元，同比减少12.85%。以上综合因素导致公司报告期内盈利水平下滑。国药现代主营业务：医药产品研发、生产与销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600025773.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0020","600420","BK0082","BK0132","BK0010","BK0239"],"gpt_icon":0},{"id":"2605650405","title":"国药现代：公司积极推进缓控释、膜剂等创新技术平台建设","url":"https://stock-news.laohu8.com/highlight/detail?id=2605650405","media":"证券日报 ","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605650405?lang=zh_cn&edition=full","pubTime":"2026-01-23 21:40","pubTimestamp":1769175600,"startTime":"0","endTime":"0","summary":"证券日报网讯 1月23日，国药现代在互动平台回答投资者提问时表示，公司始终坚持“科技引领，创新驱动”策略，加速科技创新步伐，进一步推动改良型新药和高端复杂制剂的布局，积极推进缓控释、膜剂等创新技术平台建设。合成生物学领域，主要与华东理工大学等高等院校开展有关项目的研究合作。有关公司研发具体情况，以公司披露的年度报告有关章节内容为准。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-23/doc-inhiicfu0914802.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-23/doc-inhiicfu0914802.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["600420","BK0020","BK0082","BK0010","BK0132","BK0239"],"gpt_icon":0},{"id":"2604923561","title":"每周股票复盘：国药现代（600420）注射用哌拉西林钠通过一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2604923561","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604923561?lang=zh_cn&edition=full","pubTime":"2026-01-18 02:37","pubTimestamp":1768675027,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，国药现代报收于10.63元，较上周的10.59元上涨0.38%。本周关注点公司公告汇总：注射用哌拉西林钠新增1.0g规格获批并通过一致性评价。公司公告汇总上海现代制药股份有限公司全资子公司国药集团威奇达药业有限公司收到国家药品监督管理局核准签发的《药品补充申请批准通知书》，批准注射用哌拉西林钠新增1.0g规格，并通过0.5g、1.0g、2.0g规格的仿制药质量和疗效一致性评价。截至目前，国药威奇达为此累计研发投入约612万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011800000574.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0020","BK0082","600420","BK0132","BK0010"],"gpt_icon":0},{"id":"2602254622","title":"国药现代（600420）披露全资子公司药品通过仿制药一致性评价，1月12日股价上涨0.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=2602254622","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602254622?lang=zh_cn&edition=full","pubTime":"2026-01-12 22:34","pubTimestamp":1768228453,"startTime":"0","endTime":"0","summary":"截至2026年1月12日收盘，国药现代报收于10.67元，较前一交易日上涨0.76%，最新总市值为143.1亿元。公司近日发布公告称，其全资子公司国药集团威奇达药业有限公司收到国家药品监督管理局核准签发的《药品补充申请批准通知书》，批准注射用哌拉西林钠新增1.0g规格，并通过0.5g、1.0g、2.0g规格的仿制药质量和疗效一致性评价。2024年全国公立医疗机构销售额约为19.06亿元。截至目前，国药威奇达为此累计研发投入约612万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200037497.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0082","BK0239","BK0132","600420","BK0020","BK0010"],"gpt_icon":0},{"id":"2602515813","title":"国药现代(600420.SH)子公司注射用哌拉西林钠通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2602515813","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602515813?lang=zh_cn&edition=full","pubTime":"2026-01-12 18:11","pubTimestamp":1768212706,"startTime":"0","endTime":"0","summary":"智通财经APP讯，国药现代(600420.SH)发布公告，近日，公司全资子公司国药集团威奇达药业有限公司(简称国药威奇达)收到国家药品监督管理局核准签发的《药品补充申请批准通知书》，批准注射用哌拉西林钠新增1.0g规格及本品0.5g、1.0g、2.0g通过仿制药质量和疗效一致性评价。注射用哌拉西林钠主要适用于敏感肠杆菌科细菌、铜绿假单胞菌、不动杆菌属所致的败血症、上尿路及复杂性尿路感染、呼吸道感染、胆道感染、腹腔感染、盆腔感染以及皮肤、软组织感染等。哌拉西林与氨基糖苷类联合应用亦可用于有粒细胞减少症免疫缺陷病人的感染。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1391712.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0132","600420","BK0082","BK0010","BK0020","BK0239"],"gpt_icon":0},{"id":"2594423702","title":"国药现代（600420）披露全资子公司获得药品注册证书，12月25日股价下跌0.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2594423702","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594423702?lang=zh_cn&edition=full","pubTime":"2025-12-25 22:50","pubTimestamp":1766674233,"startTime":"0","endTime":"0","summary":"截至2025年12月25日收盘，国药现代报收于10.18元，较前一交易日下跌0.1%，最新总市值为136.53亿元。该股当日开盘10.2元，最高10.21元，最低10.14元，成交额达7747.49万元，换手率为0.57%。截至目前，国药工业对该产品累计研发投入约1,040.70万元。公司此前已获得200mg规格注册证书，本次300mg规格获批有利于产品市场拓展。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122500036429.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0020","BK0010","BK0082","600420","BK0132","BK0239"],"gpt_icon":0},{"id":"2594332152","title":"国药现代(600420.SH)子公司获得富马酸喹硫平缓释片药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2594332152","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594332152?lang=zh_cn&edition=full","pubTime":"2025-12-25 16:42","pubTimestamp":1766652150,"startTime":"0","endTime":"0","summary":"智通财经APP讯，国药现代(600420.SH)发布公告，近日，公司全资子公司国药集团工业有限公司(简称国药工业)收到国家药品监督管理局核准签发的富马酸喹硫平缓释片《药品注册证书》。富马酸喹硫平缓释片是一种非典型抗精神病药物，是一种调节脑神经活动的精神类治疗药物，主要用于控制精神分裂症和双相情感障碍，具有稳定情绪、减少幻觉和改善思维混乱的作用，能帮助患者恢复正常的认知和社交功能。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385829.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"国药现代(600420.SH)子公司获得富马酸喹硫平缓释片药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0020","BK0132","BK0082","BK0239","600420","BK0010"],"gpt_icon":0},{"id":"2593408562","title":"国药现代（600420）披露选举第九届董事会成员，12月24日股价上涨0.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593408562","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593408562?lang=zh_cn&edition=full","pubTime":"2025-12-24 22:45","pubTimestamp":1766587517,"startTime":"0","endTime":"0","summary":"截至2025年12月24日收盘，国药现代报收于10.19元，较前一交易日上涨0.2%，最新总市值为136.67亿元。该股当日开盘10.18元，最高10.21元，最低10.12元，成交额达6909.02万元，换手率为0.51%。公司近日发布公告称，上海现代制药股份有限公司于2025年12月24日召开2025年第三次临时股东会，审议通过了关于变更经营范围暨修订《公司章程》的议案和关于修订《对外担保管理制度》的议案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122400041413.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0082","BK0132","600420","BK0239","BK0010","BK0020"],"gpt_icon":0},{"id":"2591642601","title":"国药现代（600420）披露拟变更经营范围并修订公司章程，12月15日股价上涨0.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591642601","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591642601?lang=zh_cn&edition=full","pubTime":"2025-12-15 22:24","pubTimestamp":1765808652,"startTime":"0","endTime":"0","summary":"截至2025年12月15日收盘，国药现代报收于10.26元，较前一交易日上涨0.1%，最新总市值为137.6亿元。该股当日开盘10.22元，最高10.29元，最低10.18元，成交额达4969.98万元，换手率为0.36%。近日，国药现代发布2025年第三次临时股东会会议资料，公告显示公司拟召开2025年第三次临时股东会，审议变更经营范围并修订《公司章程》的议案。此外，会议还涉及修订《对外担保管理制度》以及选举第九届董事会非独立董事和独立董事等相关议案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500035864.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0010","BK0132","BK0239","600420","BK0020","BK0082"],"gpt_icon":0},{"id":"2590511086","title":"国药现代（600420）披露全资子公司获得药品注册证书，12月11日股价上涨0.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590511086","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590511086?lang=zh_cn&edition=full","pubTime":"2025-12-11 22:18","pubTimestamp":1765462695,"startTime":"0","endTime":"0","summary":"截至2025年12月11日收盘，国药现代报收于10.24元，较前一交易日上涨0.79%，最新总市值为137.34亿元。该股当日开盘10.19元，最高10.29元，最低10.12元，成交额达8676.17万元，换手率为0.63%。2024年全国公立医疗机构销售额为46,887万元。截至目前，国药容生该项目累计研发投入约462万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121100041720.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","BK0082","BK0010","600420","BK0239","BK0020"],"gpt_icon":0},{"id":"2590595903","title":"国药现代(600420.SH)：布美他尼注射液获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2590595903","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590595903?lang=zh_cn&edition=full","pubTime":"2025-12-11 16:35","pubTimestamp":1765442101,"startTime":"0","endTime":"0","summary":"智通财经APP讯，国药现代(600420.SH)发布公告，近日，公司全资子公司国药集团容生制药有限公司(以下简称国药容生)收到国家药品监督管理局核准签发的布美他尼注射液《药品注册证书》。本次国药容生的布美他尼注射液获得药品注册证书并视同通过一致性评价，丰富了公司心血管药物产品群，有利于进一步增强公司在相关用药领域的综合市场竞争力，为公司未来发展带来积极影响。上述事项对公司当期经营业绩不会产生重大影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380363.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"国药现代(600420.SH)：布美他尼注射液获得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0020","BK0132","BK0010","BK0239","BK0082","600420"],"gpt_icon":0},{"id":"2590455378","title":"国药现代（600420）披露全资孙公司获得化学原料药上市申请批准通知书，12月9日股价下跌0.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590455378","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590455378?lang=zh_cn&edition=full","pubTime":"2025-12-10 08:05","pubTimestamp":1765325153,"startTime":"0","endTime":"0","summary":"近日，国药现代发布公告称，公司全资孙公司江苏威奇达药业有限公司收到国家药品监督管理局签发的关于原料药阿戈美拉汀的《化学原料药上市申请批准通知书》，批准号为2025YS01091，登记号Y20240000572，注册标准编号YBY73032025，包装规格20kg/桶。该原料药符合药品注册相关要求，可在境内生产销售。此次获批不会对公司当期经营业绩产生重大影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20251210/31854885.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["600420","BK0082","BK0239","BK0010","BK0132","BK0020"],"gpt_icon":0},{"id":"2590340316","title":"国药现代(600420.SH)：原料药阿戈美拉汀上市申请获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2590340316","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590340316?lang=zh_cn&edition=full","pubTime":"2025-12-09 16:26","pubTimestamp":1765268771,"startTime":"0","endTime":"0","summary":"智通财经APP讯，国药现代(600420.SH)公告，公司全资孙公司江苏威奇达药业有限公司(简称国药江苏威奇达)收到国家药品监督管理局核准签发的关于原料药阿戈美拉汀的《化学原料药上市申请批准通知书》。阿戈美拉汀主要通过对褪黑素受体MT1、MT2的激动及对5-HT2C拮抗的协同作用，而使患者紊乱的生物节律恢复正常，进而发挥抗抑郁效应，其制剂产品临床主要用于治疗成年抑郁症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379298.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"国药现代(600420.SH)：原料药阿戈美拉汀上市申请获批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0010","BK0020","600420","BK0132","BK0082","BK0239"],"gpt_icon":0},{"id":"2589135999","title":"国药现代（600420）披露独立董事候选人提名公告，12月8日股价下跌0.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2589135999","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589135999?lang=zh_cn&edition=full","pubTime":"2025-12-08 22:20","pubTimestamp":1765203635,"startTime":"0","endTime":"0","summary":"截至2025年12月8日收盘，国药现代报收于10.28元，较前一交易日下跌0.48%，最新总市值为137.87亿元。该股当日开盘10.33元，最高10.37元，最低10.27元，成交额达7103.54万元，换手率为0.51%。近日，上海现代制药股份有限公司董事会发布公告，提名邵瑞庆为公司第九届董事会独立董事候选人。公告显示，邵瑞庆具备独立董事任职资格，具有5年以上会计、财务等相关工作经验，拥有会计学教授职称，已通过公司第八届董事会提名委员会资格审查。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120800035000.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0020","600420","BK0082","BK0132","BK0010","BK0239"],"gpt_icon":0},{"id":"2586202898","title":"国药现代(600420.SH)子公司获盐酸氢吗啡酮注射液药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2586202898","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586202898?lang=zh_cn&edition=full","pubTime":"2025-11-28 16:19","pubTimestamp":1764317996,"startTime":"0","endTime":"0","summary":"智通财经APP讯，国药现代(600420.SH)发布公告，近日，公司全资子公司国药集团工业有限公司(简称国药工业)收到国家药品监督管理局核准签发的盐酸氢吗啡酮注射液《药品注册证书》。氢吗啡酮(Hydromorphone)又名二氢吗啡酮或双氢吗啡酮，是一种半合成的阿片类生物碱，1926年投入临床应用。盐酸氢吗啡酮注射液适用于需使用阿片类药物镇痛的患者。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1375037.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"国药现代(600420.SH)子公司获盐酸氢吗啡酮注射液药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0132","600420","BK0082","BK0010","BK0020"],"gpt_icon":0},{"id":"2585103274","title":"每周股票复盘：国药现代（600420）选举王香芬为职工董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2585103274","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585103274?lang=zh_cn&edition=full","pubTime":"2025-11-23 02:56","pubTimestamp":1763837771,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘，国药现代报收于10.18元，较上周的10.73元下跌5.13%。本周，国药现代11月17日盘中最高价报10.74元。国药现代当前最新总市值136.53亿元，在化学制药板块市值排名38/151，在两市A股市值排名1325/5167。本周关注点公司公告汇总：选举王香芬女士为第九届董事会职工代表董事。王香芬女士将与股东会选举产生的非职工代表董事共同组成第九届董事会，任期自董事会正式履职之日起至届满。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112300000694.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0082","BK0020","BK0132","BK0010","600420"],"gpt_icon":0},{"id":"2585495211","title":"国药现代（600420）披露选举职工董事公告，11月21日股价下跌2.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585495211","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585495211?lang=zh_cn&edition=full","pubTime":"2025-11-21 22:28","pubTimestamp":1763735335,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘，国药现代报收于10.18元，较前一交易日下跌2.21%，最新总市值为136.53亿元。该股当日开盘10.4元，最高10.45元，最低10.16元，成交额达1.23亿元，换手率为0.89%。公司近日发布公告称，上海现代制药股份有限公司于2025年11月20日召开第四届职工代表大会第五次会议，选举王香芬女士为公司第九届董事会职工代表董事。王香芬女士将与股东会选举产生的非职工代表董事共同组成第九届董事会，任期自董事会正式履职之日起至届满。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112100040225.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0020","600420","BK0132","BK0082","BK0239","BK0010"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1772083827671,"stockEarnings":[{"period":"1week","weight":0.0066},{"period":"1month","weight":-0.0065},{"period":"3month","weight":0.0378},{"period":"6month","weight":-0.0368},{"period":"1year","weight":-0.0156},{"period":"ytd","weight":0.0594}],"compareEarnings":[{"period":"1week","weight":0.016},{"period":"1month","weight":0.0035},{"period":"3month","weight":0.0702},{"period":"6month","weight":0.075},{"period":"1year","weight":0.2394},{"period":"ytd","weight":0.0449}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海现代制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"37848人(较上一季度减少5.26%)","perCapita":"35435股","listingDate":"2004-06-16","address":"上海市浦东新区建陆路378号","registeredCapital":"134117万元","survey":" 上海现代制药股份有限公司的主营业务是医药产品研发、生产与销售。公司的主要产品是医药中间体、原料药、化学制剂、动物疫苗、大健康。至报告期末，公司累计通过一致性评价项目（含视同）151个，其中通过自主研发和BD项目引进获得新产品批准文号59个。","listedPrice":8.08},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"国药现代(600420)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供国药现代(600420)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"国药现代,600420,国药现代股票,国药现代股票老虎,国药现代股票老虎国际,国药现代行情,国药现代股票行情,国药现代股价,国药现代股市,国药现代股票价格,国药现代股票交易,国药现代股票购买,国药现代股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"国药现代(600420)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供国药现代(600420)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}